Results 101 to 110 of about 49,935 (237)
Alimentary Pharmacology &Therapeutics, EarlyView.Among 200 patients with primary sclerosing cholangitis, 38% reported moderate to severe pruritus in the past 6 months. During 6 months of follow up, pruritus severity fluctuated significantly. Pruritus severity was linked to worse colitis activity and lower quality of life.
Richard Dean +16 more
wiley +1 more source
Alimentary Pharmacology &Therapeutics, EarlyView.In this nationwide study of patients with inflammatory bowel disease, TNF inhibitor use was associated with higher bloodstream infection rates, whereas vedolizumab and ustekinumab was not. Associations differed by pathogen species, and concomitant glucocorticoid use was associated with higher infection rates.
Cæcilie Leding +4 more
wiley +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
British Journal of Pharmacology, EarlyView.Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum
British Journal of Pharmacology, EarlyView.Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes +7 more
wiley +1 more source
, 2019 Vivy Tran,1 Rania M Shammas,2 Jenny S Sauk,1,3 David Padua1,3–41Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; 2Department of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA ...
Padua D, Sauk JS, Tran V, Shammas RM
core
British Journal of Pharmacology, EarlyView.Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu +10 more
wiley +1 more source
Chronic Myeloid Leukemia in a Patient Receiving Tofacitinib: A Case Report and Literature Review
Case Reports in Rheumatology, 2019 Background. Tofacitinib is a new oral Janus kinase inhibitor that has shown promising clinical benefit in various rheumatologic diseases. However, many concerns related to the development of malignancies have been reported with its use. Case Presentation.
Georgio Medawar +2 more
doaj +1 more source
, 2013 BackgroundThe Janus kinase (JAK) inhibitor, tofacitinib, has shown efficacy for the treatment of psoriasis in a phase IIb trial (A3921047; NCT00678210).ObjectivesTo report haematology data from the phase IIb trial, given the importance of JAK-dependent ...
Valdez, H +10 more
core
Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective
British Journal of Pharmacology, EarlyView.Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang +4 more
wiley +1 more source
The study aimed to examine the effects of the antirheumatic drug tofacitinib on metabolic syndrome associated with Rheumatoid Arthritis (RA) in a rodent model.
Vietrov, Tymur
core